Please Wait.....
Report
Global Viral Vector Vaccines Market Report and Forecast 2024-2032
Market Report I 2023-09-07 I 160 Pages I EMR Inc.
Global Viral Vector Vaccines Market and Forecast 2024-2032
Global Viral Vector Vaccines Market Outlook
The global viral vector vaccines market size was valued at USD 820.0 million in 2023, driven by the rapid advances in vaccine technology and the ongoing development of vaccines against infectious diseases and cancers. The market size is anticipated to grow at a CAGR of 19.6% during the forecast period of 2024-2032 to achieve a value of USD 4,098.9 million by 2032.
Viral Vector Vaccines: Introduction
Viral vector vaccines represent an innovative approach to vaccination that has gained significant attention, especially in the context of emerging infectious diseases and the ongoing global efforts to combat various pathogens. These vaccines use a harmless virus, known as a viral vector, as a delivery system to introduce genetic material from a target pathogen into the human body. This genetic material stimulates the immune system to produce a protective response against the target pathogen.
Significance of Viral Vector Vaccines:
Viral vector vaccines are significant because they offer a versatile and effective platform for developing vaccines against a wide range of infectious diseases, including viral infections and certain cancers. They are particularly valuable in situations where traditional vaccine development methods may face challenges.
Key Trends in the Global Viral Vector Vaccines Market
- Expanding Vaccine Development Platforms: Researchers are exploring a variety of viral vectors, including adenoviruses, vesicular stomatitis viruses (VSVs), and adeno-associated viruses (AAVs), for vaccine development. This diversity allows for targeting a wide range of diseases, including infectious diseases and certain cancers.
- COVID-19 Vaccine Development and Beyond: The COVID-19 pandemic has accelerated the development and adoption of viral vector vaccines. The success of COVID-19 vaccines using viral vectors has sparked interest in applying this technology to other infectious diseases, such as HIV and influenza.
- Cancer Vaccines: Viral vector vaccines are being investigated as a tool in cancer immunotherapy. They can deliver tumor-specific antigens or genetic material to trigger an immune response against cancer cells. The market for cancer vaccines is expected to grow as more research and clinical trials take place.
- Gene Therapies: Viral vectors are not limited to vaccines; they are also essential in gene therapy applications. As gene therapy becomes more common in treating genetic disorders, viral vectors are playing a crucial role in delivering therapeutic genes.
Global Viral Vector Vaccines Market Segmentations
The market can be categorised into type, application, disease, end user and region.
Market Breakup by Type
- Adenovirus
- Retrovirus
- Plasmid DNA
- AAV
- Lentivirus
- Others
Market Breakup by Application
- Antisense and RNAi
- Gene Therapy
- Cell Therapy
- Vaccinology
Market Breakup by Disease
- Cancer
- Genetic Disorders
- Infectious Diseases
- Others
Market Breakup by End User
- Pharmaceutical
- Biopharmaceutical Companies
- Research Institute
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Viral Vector Vaccines Market Overview
The global viral vector vaccines market is a rapidly growing segment within the broader vaccine industry. Viral vector vaccines use harmless viruses as vehicles, or vectors, to deliver genetic material from a target pathogen into the human body. This genetic material stimulates an immune response and triggers the production of antibodies and immune memory cells, providing protection against specific diseases. The global viral vector vaccines market has witnessed substantial growth in recent years, and this trend is expected to continue. Factors contributing to market growth include advances in vaccine technology, increasing investment in research and development, and the urgent need for vaccines against emerging infectious diseases.
North America and Europe are major players in the global viral vector vaccines market due to their advanced healthcare infrastructure, robust research and development capabilities, and substantial investment in vaccine development. Emerging markets in Asia Pacific and Latin America are showing significant growth potential, driven by increasing healthcare awareness and infrastructure development.
Key Players in the Global Viral Vector Vaccines Market
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in global viral vector vaccines market are as follows:
- Novasep
- Merck KGaA
- Charles River Laboratories
- uniQure N.V
- Waisman Biomanufacturing
- Creative-Biogene
- Aldevron
- Addgene
- Oxford Biomedical
- Thermo Fisher Scientific Inc
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1Preface
1.1Objectives of the Study
1.2Key Assumptions
1.3Report Coverage - Key Segmentation and Scope
1.4Research Methodology
2Executive Summary
3Global Viral Vector Vaccines Market Overview
3.1Global Viral Vector Vaccines Market Historical Value (2017-2023)
3.2Global Viral Vector Vaccines Market Forecast Value (2024-2032)
4Global Viral Vector Vaccines Market Landscape
4.1Global Viral Vector Vaccines: Developers Landscape
4.1.1Analysis by Year of Establishment
4.1.2Analysis by Company Size
4.1.3Analysis by Region
4.2Global Viral Vector Vaccines: Product Landscape
4.2.1Analysis by Type
4.2.2Analysis by Disease
4.2.3Analysis by Applications
5Global Viral Vector Vaccines Market Dynamics
5.1Market Drivers and Constraints
5.2SWOT Analysis
5.3Porter's Five Forces Model
5.4Key Demand Indicators
5.5Key Price Indicators
5.6Industry Events, Initiatives, and Trends
5.7Value Chain Analysis
6Global Viral Vector Vaccines Market Segmentation
6.1Global Viral Vector Vaccines Market by Type
6.1.1Market Overview
6.1.2Adenovirus
6.1.3Retrovirus
6.1.4Plasmid DNA
6.1.5AAV
6.1.6Lentivirus
6.1.7Others
6.2Global Viral Vector Vaccines Market by Applications
6.2.1Market Overview
6.2.2Antisense and RNAi
6.2.3Gene Therapy
6.2.4Cell Therapy
6.2.5Vaccinology
6.3Global Viral Vector Vaccines Market by Disease
6.3.1Market Overview
6.3.2Cancer
6.3.3Genetic Disorders
6.3.4Infectious Diseases
6.3.5Others
6.4Global Viral Vector Vaccines Market by End User
6.4.1Market Overview
6.4.2Pharmaceutical
6.4.3Biopharmaceutical Companies
6.4.4Research Institute
6.5Global Viral Vector Vaccines Market by Region
6.5.1Market Overview
6.5.2North America
6.5.3Europe
6.5.4Asia Pacific
6.5.5Latin America
6.5.6Middle East and Africa
7North America Viral Vector Vaccines Market
7.1Market Share by Country
7.2United States of America
7.3Canada
8Europe Viral Vector Vaccines Market
8.1Market Share by Country
8.2United Kingdom
8.3Germany
8.4France
8.5Italy
8.6Others
9Asia Pacific Viral Vector Vaccines Market
9.1Market Share by Country
9.2China
9.3Japan
9.4India
9.5ASEAN
9.6Australia
9.7Others
10Latin America Viral Vector Vaccines Market
10.1Market Share by Country
10.2Brazil
10.3Argentina
10.4Mexico
10.5Others
11Middle East and Africa Viral Vector Vaccines Market
11.1Market Share by Country
11.2Saudi Arabia
11.3United Arab Emirates
11.4Nigeria
11.5South Africa
11.6Others
12Regulatory Framework
12.1Regulatory Overview
12.1.1US FDA
12.1.2EU EMA
12.1.3INDIA CDSCO
12.1.4JAPAN PMDA
12.1.5Others
13Patent Analysis
13.1Analysis by Type of Patent
13.2Analysis by Publication year
13.3Analysis by Issuing Authority
13.4Analysis by Patent Age
13.5Analysis by CPC Analysis
13.6Analysis by Patent Valuation
13.7Analysis by Key Players
14Grants Analysis
14.1Analysis by year
14.2Analysis by Amount Awarded
14.3Analysis by Issuing Authority
14.4Analysis by Grant Application
14.5Analysis by Funding Institute
14.6Analysis by NIH Departments
14.7Analysis by Recipient Organization
15Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2Analysis by Trial Status
15.3Analysis by Trial Phase
15.4Analysis by Therapeutic Area
15.5Analysis by Geography
16Funding and Investment Analysis
16.1Analysis by Funding Instances
16.2Analysis by Type of Funding
16.3Analysis by Funding Amount
16.4Analysis by Leading Players
16.5Analysis by Leading Investors
16.6Analysis by Geography
17Partnership and Collaborations Analysis
17.1Analysis by Partnership Instances
17.2Analysis by Type of Partnership
17.3Analysis by Leading Players
17.4Analysis by Geography
18Supplier Landscape
18.1Novasep
18.1.1Financial Analysis
18.1.2Product Portfolio
18.1.3Demographic Reach and Achievements
18.1.4Mergers and Acquisitions
18.1.5Certifications
18.2Merck KGaA
18.2.1Financial Analysis
18.2.2Product Portfolio
18.2.3Demographic Reach and Achievements
18.2.4Mergers and Acquisitions
18.2.5Certifications
18.3Charles River Laboratories
18.3.1Financial Analysis
18.3.2Product Portfolio
18.3.3Demographic Reach and Achievements
18.3.4Mergers and Acquisitions
18.3.5Certifications
18.4uniQure N.V
18.4.1Financial Analysis
18.4.2Product Portfolio
18.4.3Demographic Reach and Achievements
18.4.4Mergers and Acquisitions
18.4.5Certifications
18.5Waisman Biomanufacturing
18.5.1Financial Analysis
18.5.2Product Portfolio
18.5.3Demographic Reach and Achievements
18.5.4Mergers and Acquisitions
18.5.5Certifications
18.6Creative-Biogene
18.6.1Financial Analysis
18.6.2Product Portfolio
18.6.3Demographic Reach and Achievements
18.6.4Mergers and Acquisitions
18.6.5Certifications
18.7Aldevron
18.7.1Financial Analysis
18.7.2Product Portfolio
18.7.3Demographic Reach and Achievements
18.7.4Mergers and Acquisitions
18.7.5Certifications
18.8Addgene
18.8.1Financial Analysis
18.8.2Product Portfolio
18.8.3Demographic Reach and Achievements
18.8.4Mergers and Acquisitions
18.8.5Certifications
18.9Oxford Biomedical
18.9.1Financial Analysis
18.9.2Product Portfolio
18.9.3Demographic Reach and Achievements
18.9.4Mergers and Acquisitions
18.9.5Certifications
18.10Thermo Fisher Scientific Inc
18.10.1Financial Analysis
18.10.2Product Portfolio
18.10.3Demographic Reach and Achievements
18.10.4Mergers and Acquisitions
18.10.5Certifications
19Key Opinion Leaders (KOL) Insights (Additional Insight)
20Company Competitiveness Analysis (Additional Insight)
20.1Very Small Companies
20.2Small Companies
20.3Mid-Sized Companies
20.4Large Companies
20.5Very Large Companies
21Payment Methods (Additional Insight)
21.1Government Funded
21.2Private Insurance
21.3Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security